Collaboration Set to Explore Neuropsychiatric Treatment Using Non-Invasive, Targeted Drug Delivery via Novel Nanoparticle and Ultrasound Technology

合作计划通过新型纳米粒子和超声波技术探索使用非侵入性靶向药物递送的神经精神治疗

MOUNTAIN VIEW, Calif., Dec. 7, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical technology company focused on non-invasive brain treatments, is pleased to announce a new strategic agreement with Stanford Medicine, working with radiologist Dr. Raag Airan, Assistant Professor, and neurologist-psychiatrist Dr.

加利福尼亚州山景城（MOUNTAIN VIEW），2023年12月7日/PRNewswire/--Cordance Medical是一家专注于非侵入性脑部治疗的开创性医疗技术公司，很高兴宣布与斯坦福医学公司（Stanford Medicine）达成新的战略协议，与放射科医生、助理教授拉格·艾兰（Raag Airan）博士和神经科精神科医生拉格·艾兰（Dr。

Nolan Williams, Associate Professor, Stanford Medicine. This collaboration will combine Cordance's breakthrough NeuroAccess™ device with Dr. Airan's novel nanoparticle drug development to establish a new standard for precision medicine in neurology and psychiatry. Dr. Airan is also an Advisor with Cordance Medical..

诺兰·威廉姆斯，斯坦福医学院副教授。这项合作将结合Cordance突破性的NeuroAccess™该设备与艾兰博士的新型纳米颗粒药物开发一起，为神经病学和精神病学中的精密医学建立了新标准。Airan博士也是Cordance Medical的顾问。。

The combined expertise of Cordance and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain. This method enables focal noninvasive drug delivery with the Airan Lab's pioneering technology of Ultrasonic Drug Uncaging, leveraging the capabilities of NeuroAccess beyond its original function of blood-brain barrier (BBB) opening..

Cordance以及Airan和Williams实验室的综合专业知识将使NeuroAccess被用于提供载药纳米颗粒的新应用，从而为大脑提供靶向药物输送。该方法利用Airan实验室开创性的超声波药物解封技术实现了局灶性无创药物输送，利用了神经通路的功能，超越了血脑屏障（BBB）的原始功能。。

'With this agreement, we're taking a critical step forward in the field of precision neuropsychiatry,' said Ryan Dittamore, CEO of Cordance. 'Our NeuroAccess platform, when paired with Dr. Airan's novel nanoparticles, has the potential to revolutionize patient care by providing more precise control of neural activity.

Cordance首席执行官瑞安·迪特莫尔（RyanDittamore）说，通过这项协议，我们在精准神经精神病学领域迈出了关键的一步我们的NeuroAccess平台与艾兰博士的新型纳米颗粒相结合，有可能通过提供更精确的神经活动控制来彻底改变患者护理。

We're thrilled to collaborate with the Airan and Williams Labs, blending our technological advancements to create a future where neurological and psychiatric treatment is both safer and more effective.'.

我们很高兴与Airan和Williams实验室合作，融合我们的技术进步，创造一个神经和精神治疗更安全、更有效的未来。”。

The NeuroAccess device will be used to 'uncage' drug-loaded nanoparticles within targeted areas of the brain. This unique approach facilitates the diffusion of the drug payload across an intact BBB, promising targeted and highly-localized therapy, while minimizing side effects by limiting drug action outside of the region of interest, with potential applications in treating a wide range of neurologic and neuropsychiatric disorders..

NeuroAccess设备将用于在大脑的目标区域内“解开”载药纳米颗粒。这种独特的方法有助于药物有效载荷在完整的BBB中扩散，有望实现靶向和高度局部化的治疗，同时通过限制感兴趣区域之外的药物作用来最大程度地减少副作用，在治疗各种神经和神经精神疾病方面具有潜在的应用。。

As the PIs of this clinical study Drs. Airan and Williams at Stanford Medicine said, 'Our labs have made significant strides in developing ultrasonic drug uncaging using drug-loaded nanoparticles that can be triggered using short, low-intensity ultrasound pulses. We believe Cordance's NeuroAccess device will be an important tool for enabling targeted drug delivery to the brain using our nanoparticles by applying focused ultrasound precisely where the uncaging event is needed.

正如这项临床研究的PI斯坦福医学院（Stanford Medicine）的艾兰（Airan）博士和威廉姆斯（Williams）博士所说，“我们的实验室在开发超声波药物解封方面取得了重大进展，该超声波药物解封使用载药纳米颗粒，可以使用短的低强度超声波脉冲触发。我们相信，Cordance的NeuroAccess设备将成为一种重要工具，可以通过将聚焦超声波精确地应用于需要解封事件的地方，使用我们的纳米颗粒将药物靶向输送到大脑。

This collaboration marks a significant milestone in our journey towards establishing a new, non-invasive treatment paradigm through precision neuro-pharmacology.'.

这一合作标志着我们通过精确神经药理学建立新的非侵入性治疗范例的旅程中的一个重要里程碑。”。

The first-in-human trial of this technology enabled by this agreement will employ a nanoparticle-bound version of ketamine, aiming to demonstrate the effectiveness of this approach in a clinical setting for patients with chronic pain.

该协议启用的该技术的首次人体试验将采用纳米颗粒结合的氯胺酮版本，旨在证明该方法在慢性疼痛患者的临床环境中的有效性。

'It's truly invigorating to participate in this transformative research,' shares Dr. Ramamurthy, CTO and co-founder of Cordance Medical. 'With this study, we are set to demonstrate the expansive applicability of NeuroAccess technology. From neuro-oncology to neuropsychiatry, we're pushing boundaries to make a meaningful impact on patient care.'.

Cordance Medical首席技术官兼联合创始人拉马穆西（Ramamurthy）博士说，参加这项变革性研究确实令人振奋通过这项研究，我们将证明NeuroAccess技术的广泛适用性。从神经肿瘤学到神经精神病学，我们正在突破界限，对患者护理产生有意义的影响。”。

About Cordance Medical:

关于Cordance Medical：

Cordance Medical is a healthcare technology company dedicated to revolutionizing patient care with its innovative NeuroAccess platform. Its cutting-edge technology facilitates the non-invasive opening of the BBB, enhancing drug delivery, and enabling liquid biopsy for brain tumors. The company is driven by a mission to make these complex healthcare procedures accessible to all patients.

Cordance Medical是一家医疗保健技术公司，致力于通过其创新的NeuroAccess平台彻底改变患者护理。其尖端技术有助于无创打开血脑屏障，增强药物输送，并为脑肿瘤进行液体活检。该公司的使命是使所有患者都可以使用这些复杂的医疗保健程序。

For more information, please visit www.cordancemedical.com..

有关更多信息，请访问www.cordancemedical.com。。

Learn more about Stanford's Noninvasive Neurointerventions Lab:

了解有关斯坦福大学无创神经干预实验室的更多信息：

The Noninvasive Neurointerventions Lab, headed by Dr. Raag Airan, Assistant Professor of Radiology at Stanford University, specializes in the development of novel noninvasive interventions to address diseases of the nervous system, including the development of ultrasound-sensitive nanoparticles capable of carrying various drugs of neuropsychiatric interest.

非侵入性神经干预实验室由斯坦福大学放射学助理教授拉格·艾兰博士领导，专门研究开发新型非侵入性干预措施，以解决神经系统疾病，包括开发能够携带各种神经精神病学药物的超声敏感纳米颗粒。

They are known for their innovative work in the field of ultrasonic drug uncaging, a novel approach that could redefine how neurologic and psychiatric disorders are treated..

他们以在超声波药物解封领域的创新工作而闻名，这是一种可以重新定义神经和精神疾病治疗方式的新方法。。

Learn more about Stanford's Brain Stimulation Lab:

了解有关斯坦福大脑刺激实验室的更多信息：

The Brain Stimulation Lab, headed by Dr. Nolan Williams has a focus on the development of novel therapeutics. The BSL's first innovation, SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), has FDA Breakthrough Status and FDA Clearance for Treatment Resistant Depression. Dr. Williams has worked alongside a team at Stanford to develop candidate predictive neuroimaging-based biomarkers of treatment efficacy..

由诺兰·威廉姆斯博士领导的大脑刺激实验室专注于新型疗法的开发。BSL的第一项创新SAINT（斯坦福加速智能神经调节疗法）具有FDA突破性地位，并获得FDA对难治性抑郁症的批准。威廉姆斯博士与斯坦福大学的一个团队合作，开发基于预测性神经影像学的候选治疗效果生物标志物。。

SOURCE Cordance Medical

源Cordance Medical